What GLP-1 Dose Reduces Alcohol Cravings?

The alcohol craving effects in the published semaglutide trial showed up at low, early-titration doses, not at the maximum doses used for weight management. That surprises almost everyone.

What You'll Discover:

• The exact doses used in the published semaglutide alcohol trial.

• Why low doses were enough to move the craving measures.

• Why a higher dose is not automatically better for this purpose.

• What titration is actually there to do.

• Where GLP-1 medications stand against an option that is already FDA-approved.

If you have heard that GLP-1 medications reduce drinking, the obvious next question is how much you would need.

The answer from the published research is smaller than most people expect, and that turns out to be the most useful thing on this page.

The Short Answer on Dose

In the randomized trial that produced the clearest craving data, the effects showed up during the lowest doses of a standard titration schedule.

Participants were not on maximum weight-management doses. They were on the starting steps that most people pass through in their first two months.

That is a genuinely interesting finding. It is also not a prescription. Dosing decisions belong to a physician who can see your full medical history.

What the Published Trial Actually Used

The key study is a phase 2, double-blind, randomized trial of once-weekly semaglutide in adults with alcohol use disorder, published in JAMA Psychiatry in 2025.

It enrolled 48 non-treatment-seeking adults with alcohol use disorder across 9 weeks of outpatient treatment, with weekly clinic visits.

That is a small trial. It is worth holding that in mind alongside everything that follows.

The Exact Schedule

The semaglutide group followed a completely standard titration, the same one used when starting the medication for other reasons.

Participants received 0.25 mg once weekly for 4 weeks. Then 0.5 mg once weekly for 4 weeks. Then a single week at 1.0 mg, contingent on tolerability.

That is the whole schedule. No maintenance phase at higher doses, no extended run-in period.

When the Results Were Measured

This is the part that answers the dosing question directly.

The two lowest dose sequences, 0.25 mg across weeks 1 through 4 and 0.5 mg across weeks 5 through 8, were the doses in place before the primary outcome was collected.

Relative to placebo, low-dose semaglutide reduced the amount of alcohol consumed during a post-treatment laboratory self-administration procedure. It also significantly reduced weekly alcohol craving.

So the craving signal was present at doses most people would think of as a starting point rather than a therapeutic target.

Trial Doses and What They Mean for You

The gap between that bottom row and everything above it is the whole point of this article.

What "Low Dose" Means in Context

It helps to see the alcohol trial doses next to the doses used for the medication's approved purposes.

For weight management, the recommended maintenance dose is 2.4 mg once weekly, reached after a months-long climb.

The alcohol trial never went above 1.0 mg, and its main measurements were taken at 0.25 mg and 0.5 mg.

So the doses associated with reduced craving in that study sit near the bottom of the range people are used to hearing about, at roughly a fifth of the weight-management maintenance dose.

That is the single most useful takeaway here, and it runs against the intuition most people bring to the question.

Why Higher Is Not Automatically Better

There is a natural assumption that if a little helps, more will help more. For this purpose that assumption does not hold up.

The alcohol-related effects appear to run through central reward pathways rather than through appetite suppression alone. Those systems are related, but they are not the same dial.

Titration Exists to Limit Side Effects

Every GLP-1 dosing schedule starts low and climbs slowly for one specific reason.

Gastrointestinal side effects, nausea above all, are the most common problem and they scale with both dose and speed of escalation. Titration is the mechanism that keeps them manageable enough that people continue.

Pushing a dose higher than needed trades a real side effect burden for a benefit that has not been demonstrated. We cover what those effects look like day to day in our article on GLP-1 side effects when the goal is alcohol.

More Medication Is Not More Reward Blunting

The trial's own design is informative here. Craving reductions were measured during the low-dose phases, and the single week at 1.0 mg came after the main outcome window.

Nothing in the published data suggests that going higher produces a larger effect on drinking. That question simply has not been answered yet.

Anyone who tells you that a maximum dose works better for alcohol is going beyond the evidence.

What the Broader Evidence Shows

The semaglutide trial does not stand alone. A systematic review and meta-analysis of GLP-1 receptor agonists and alcohol consumption pooled randomized and observational studies in adults with hazardous drinking or alcohol use disorder.

It found reductions in alcohol use as measured by standard screening scores, along with beneficial effects on consumption, relapse, and alcohol-related outcomes.

That is encouraging, and it is still early. Most of the underlying studies were designed around diabetes or weight management, with alcohol measured as a secondary outcome.

Real-world registry data points the same direction, which is a different kind of evidence than a controlled trial and worth weighing as such.

If your question is about timing rather than the number, we cover that in our piece on how long for a GLP-1 to reduce alcohol cravings.

Why the Trial Population Matters for Your Dose Question

Small details in study design change how much a number should mean to you.

The participants were non-treatment-seeking adults with alcohol use disorder. They had not walked in asking for help with drinking, which is a different group from most people reading this.

They were also, on average, around 40 years old, and most were female. Every trial has a population, and results do not automatically transfer outside it.

That does not undermine the finding. It means the doses that worked in that group are a research result rather than a personal target.

The follow-up work now underway includes larger and longer trials, and those are where dosing guidance for drinking will eventually come from.

The Oral Versus Injectable Question

Semaglutide comes in more than one form, and people sometimes assume the numbers transfer between them.

They do not. The injectable and oral preparations use different dose ranges entirely, because they are absorbed differently.

The alcohol trial used the once-weekly injectable form. Nothing in it says anything about what an equivalent oral dose would be for this purpose.

If you are on the tablet form for another reason, the milligram figures above are not a comparison point for you.

What a Prescriber Will Actually Ask

If you bring this up at an appointment, the conversation will not start at dosing. It will start somewhere else entirely.

Expect questions about how much you drink in a typical week, whether you have tried to cut back before, your history with pancreatitis or thyroid conditions, and what other medications you take.

Expect questions about your goal too. Cutting back and stopping entirely are both legitimate, and they can point toward different approaches.

The dose comes last, after all of that. That ordering is not bureaucracy, it is how the decision actually gets made responsibly.

Dosing Is a Physician Decision, Every Time

None of the numbers above are a target for you to aim at on your own.

Semaglutide is approved by the FDA under three brand names, each with its own indications, preparations, and dosages, as documented in the StatPearls reference on semaglutide.

Which formulation, which starting dose, and how quickly to move all depend on your medical history, your other medications, your kidney and pancreatic health, and what is actually being treated.

A physician also has to weigh contraindications that have nothing to do with drinking. Our overview of whether GLP-1 medication for alcohol is safe walks through what gets screened before anyone writes a prescription.

Do not adjust your own dose based on an article, including this one.

The Approval Gap That Changes the Conversation

Here is the context a dosing article should not skip.

GLP-1 medications are not FDA-approved for alcohol use disorder. Prescribing one for drinking is off-label, which is legal and routine in medicine, but it means there is no approved dose for this purpose to point to.

That is not a small technicality. It affects insurance coverage, it affects what a pharmacy will fill without friction, and it affects how much dosing guidance exists.

Naltrexone sits in a completely different position. The StatPearls reference on naltrexone documents that it is FDA-approved for alcohol use disorder, available as a 50 mg oral tablet.

That approval means the dosing question has a settled answer, decades of trial data behind it, and far fewer obstacles between you and a prescription.

We compare the two directly in our article on naltrexone versus GLP-1 medication for alcohol use disorder.

What to Do With This Information

There are really three situations people are in when they search this.

If you are already on a GLP-1 for weight or diabetes and have noticed you want alcohol less, that matches what the research is finding. Tell your prescriber, because it is useful clinical information.

If you are considering a GLP-1 specifically for drinking, the honest framing is that the evidence is promising and preliminary. A 48-person trial is a starting point, not a settled case.

If drinking less is your actual goal and you have no other reason to be on a GLP-1, there is an approved medication with a known dose and thirty years of evidence behind it. That belongs on the table.

For a lot of people the useful conversation is not one medication versus the other. It is which one fits the goal directly in front of you.

Conclusion

The published semaglutide trial found craving reductions at 0.25 mg and 0.5 mg once weekly, which are the first two steps of an ordinary titration schedule.

Higher has not been shown to be better for drinking, and titration exists to keep gastrointestinal side effects tolerable rather than to chase a bigger effect.

Every one of those decisions belongs to a physician who can see your whole picture, rather than to a number you talk yourself into.

Being curious about this research is completely reasonable. So is wanting a straightforward option while the science catches up, and there is no contradiction between the two.

You do not need to have a crisis or a label to ask a doctor about any of this. Wanting to drink less is reason enough.

Frequently Asked Questions

What dose of semaglutide was used in the alcohol trial?

Participants received 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for 4 weeks, then 1.0 mg for a final week if tolerated. The craving reductions were measured during the low-dose phases.

Do I need a high GLP-1 dose to reduce alcohol cravings?

The published evidence does not show that. Effects appeared at low, early-titration doses, and no trial has demonstrated a larger drinking effect at maximum doses.

Is a GLP-1 approved for alcohol use disorder?

No. Using one for drinking is off-label. Naltrexone is FDA-approved for alcohol use disorder and has an established 50 mg oral dose.

Can I increase my own GLP-1 dose to drink less?

No. Dose changes are a physician decision, and raising a dose increases gastrointestinal side effect risk without any evidence of a larger effect on drinking.

Why does titration start so low?

Slow escalation limits nausea and other gastrointestinal effects, which are the most common reason people stop these medications. The whole schedule is built around tolerability.

Does the effect on drinking depend on losing weight?

Not entirely. Research points to central reward pathways as part of the mechanism, which is why craving effects can appear before significant weight change.

If drinking less is the real goal, it is worth knowing all of your options, including the one that already has an approved dose behind it.

Take the online Alcohol Use Assessment and a physician can help you sort out what fits your situation.